16,584 Shares of Ascendis Pharma A/S $ASND Acquired by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,584 shares of the biotechnology company’s stock, valued at approximately $3,778,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 69 shares during the period. Allworth Financial LP boosted its stake in shares of Ascendis Pharma A/S by 103.4% in the 2nd quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 122 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Ascendis Pharma A/S by 94.9% during the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock worth $70,000 after buying an additional 148 shares during the period. IFP Advisors Inc increased its position in shares of Ascendis Pharma A/S by 3,491.7% during the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company’s stock worth $115,000 after buying an additional 419 shares during the period. Finally, Farther Finance Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $139,000.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $256.82 on Monday. The stock has a market cap of $16.02 billion, a price-to-earnings ratio of 19.92 and a beta of 0.40. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15. The business’s 50 day moving average is $242.50 and its 200 day moving average is $239.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million during the quarter, compared to analysts’ expectations of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. On average, sell-side analysts forecast that Ascendis Pharma A/S will post 3.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on ASND shares. Canaccord Genuity Group set a $268.00 price objective on Ascendis Pharma A/S in a research report on Monday, October 26th. HC Wainwright set a $344.00 target price on Ascendis Pharma A/S in a research report on Thursday, September 10th. Wedbush reaffirmed an “outperform” rating and set a $327.00 target price on shares of Ascendis Pharma A/S in a research note on Tuesday, September 1st. BMO Capital Markets reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Finally, Raymond James Financial downgraded Ascendis Pharma A/S from a “strong-buy” rating to an “outperform” rating and set a $287.00 target price for the company. in a report on Tuesday, September 15th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $305.95.

Insider Buying and Selling at Ascendis Pharma A/S

In related news, Director Jean-Jacques Bienaimé purchased 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average cost of $246.33 per share, with a total value of $492,660.00. Following the acquisition, the director owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the transaction, the senior vice president owned 3,000 shares in the company, valued at approximately $810,570. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 40.00% of the stock is currently owned by insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines.

Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.